Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT ) 5.020 +0.370 (+7.96%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 102,083 Open 4.720 Bid (Size) 4.950 (1) Ask (Size) 5.100 (1) Prev. Close 4.650 Today's Range 4.550 - 5.140 52wk Range 4.440 - 12.10 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium December 10, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session November 14, 2024 Via Benzinga Performance YTD -39.45% -39.45% 1 Month -2.52% -2.52% 3 Month -18.51% -18.51% 6 Month -19.94% -19.94% 1 Year -40.17% -40.17% More News Read More Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug November 14, 2024 Via Benzinga S&P 500 Moves Lower; US Crude Oil Inventories Increase November 14, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Dow Falls Over 100 Points; US Producer Prices Rise In October November 14, 2024 Via Benzinga Topics Stocks Exposures US Equities US Stocks Edge Lower; Cisco Earnings Top Views November 14, 2024 Via Benzinga Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort November 14, 2024 Via AB Newswire Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer November 14, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update October 28, 2024 Via News Direct PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update October 28, 2024 From PESG Research Via Business Wire Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics October 23, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session October 16, 2024 Via Benzinga Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference October 07, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian September 19, 2024 Via News Direct Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment September 16, 2024 Via News Direct PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch September 16, 2024 From PESG Research Via Business Wire Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 05, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data August 29, 2024 Via News Direct Exposures Product Safety Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT) August 15, 2024 Via AB Newswire Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market July 18, 2024 Via AB Newswire Precision Medicine M&A is Transforming the Future of the Biotech Industry June 17, 2024 Via AB Newswire 7 Penny Biotech Stocks to Triple Your Investment May 28, 2024 Via InvestorPlace Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference May 16, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 May 07, 2024 Via InvestorPlace Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines April 08, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
